Ergoteles’s Axsome Therapeutics AXSM Stock Holding History

Ergoteles’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,700	Closed	-$385K	–	1211
2021 Q2	$385K	Sell	5,700 -2,700	-32%	-$162K	0.01%	934
2021 Q1	$476K	Buy	+8,400	New	+$591K	0.01%	492

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Ergoteles's AXSM Position: Q3 2021 in Review

Ergoteles sold out of Axsome Therapeutics (AXSM) in Q3 2021, closing a stake of 5,700 shares — an estimated $385K sold.

Ergoteles first reported a position in AXSM in Q1 2021 and held it in 2 quarters. The position peaked at $476K in Q1 2021. 171 funds tracked by Wall St. Rank hold AXSM as of Q3 2021.

Ergoteles reported no remaining Axsome Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 5,700 Axsome Therapeutics shares in Q3 2021, an estimated $385K.
Ergoteles first reported a position in Axsome Therapeutics in Q1 2021 and held it in 2 quarters.
Ergoteles's Axsome Therapeutics position peaked at $476K in Q1 2021.
171 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.